Showing results (41-50 of 127) with videos related to
Sort By:
Pageof 13
Journal of Viral Hepatitis|August 27, 2021
Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trialsEdward Gane, Victor de Ledinghen, Douglas E Dylla, et al.Journal of Gastroenterology and Hepatology|March 3, 2006
Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of lifeSanjeev Arora, Christopher O'Brien, Stefan Zeuzem, et al.The Lancet. Gastroenterology & Hepatology|July 8, 2021
Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trialMan-Fung Yuen, Xue Zhou, Edward Gane, et al.Liver International : Official Journal of the International Association for the Study of the Liver|February 27, 2022
Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up studyFred Poordad, Franco Felizarta, Betty B Yao, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2016
Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH TrialAndrew X Zhu, Yoon-Koo Kang, Olivier Rosmorduc, et al.Annals of the New York Academy of Sciences|August 4, 2015
Development of sofosbuvir for the treatment of hepatitis C virus infectionEric Lawitz, Ira M Jacobson, David R Nelson, et al.Hepatology (Baltimore, Md.)|April 5, 2012
Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II studyMichael P Manns, Edward Gane, Maribel Rodriguez-Torres, et al.Journal of Gastroenterology|March 15, 2019
Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infectionAtsushi Naganuma, Kazuaki Chayama, Kazuo Notsumata, et al.Vaccine|November 23, 2007
Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudinePierre Vandepapelière, George K K Lau, Geert Leroux-Roels, et al.Hepatology (Baltimore, Md.)|October 26, 2019
Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral InfectionMarianne Martinello, Chloe Orkin, Graham Cooke, et al.Pageof 13